^
14h
P1, N=24, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin)
23h
Trastuzumab is a monoclonal antibody against HER2 that prevents HER2-mediated signaling; it is administered mainly in HER2-positive cancers, such as breast, colorectal, biliary tract, and non-small-cell lung cancers...PD/PDL-1 inhibitors can cause myocarditis, rare but potentially fulminant and associated with a high fatality rate. CAR-T therapy is associated with several cardiac toxic effects, mainly in the context of a systemic adverse effect, the cytokines release syndrome.
Review • Journal • Adverse events
|
HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1)
|
HER-2 positive
|
Herceptin (trastuzumab)
1d
Collectively, these results indicate that AAII present in the plant extract AA enhances the genotoxic properties of AAI (i.e., AAI DNA adduct formation). As patients suffering from AAN and BEN are always exposed to the plant extract (i.e., AAI/AAII mixture), our findings are crucial to better understanding host factors critical for AAN- and BEN-associated urothelial malignancy.
Preclinical • Journal
|
NQO1 (NAD(P)H dehydrogenase, quinone 1)
1d
Additionally, LINC00355 regulated the migration, invasion, and EMT ability of bladder cancer cells through modulating HMGA2 expression via sponging miR-424-5p. LINC00355 promoted migration, invasion, and EMT ability of bladder cancer through elevating HMGA2 expression via acting as a sponge for miR-424-5p.
Journal
|
MIR424 (MicroRNA 424) • HMGA2 (High mobility group AT-hook 2)
2d
Oncology planned to initiate chemotherapy as an outpatient, unfortunately, the patient was unstable for a PET-scan or further testing and failed treatments with Docetaxel and Gemcitabine. This case illustrates the possibility of extensive metastasis from an osteoclastic sarcoma without an obvious primary. These can be very aggressive as seen in our patient and the present therapies may not be sufficient to manage them and better understanding of the pathology and therapeutics is necessary.
Clinical
|
AFP (Alpha-fetoprotein) • CEACAM5 (CEA Cell Adhesion Molecule 5) • VIM (Vimentin) • CD68 (CD68 Molecule) • Cancer antigen 19-9
|
gemcitabine • docetaxel
3d
The established canine TCC cell lines responded with greater sensitivity to sorafenib than to vemurafenib, which is known as a specific BRAF inhibitor in human cancer. Our results demonstrated that canine TCC cells showed different responses compared to human cancer with the BRAF V600E mutation. These cell lines would be valuable research materials to develop therapeutic strategies for canine TCC patients.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF mutation • BRAF V600
|
Zelboraf (vemurafenib) • Nexavar (sorafenib)
3d
Thus, cells such as natural killer (NK) cells, macrophages, dendritic cells, neutrophils but also MHC-restricted CD4 and CD8 T cells and γδ T cells may play an important role and can be one the main effectors in BCG therapy. Here, we discuss the role of BCG therapy in bladder cancer and other cancers, including current strategies and their impact on the generation and sustainability of protective antitumor immunity against bladder cancer.
Review • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
3d
Somatic sequencing performed on their respective tumors could help discern the etiology of the component tumors, highlighting the role of somatic evaluation in these cases. Paired examination of somatic and germline findings provided a more complete landscape of genome alterations in cancer development.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
3d
In conclusion, tumors with high HRD score exhibit an immune-sensitive TME. The HRD-high genotype is a promising marker for identifying ICI therapy responders among breast cancer patients.
Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
HRD (Homologous Recombination Deficiency)
|
HRD • High HRD score
3d
In conclusion, MTHFD2 localizes in the nucleus to perform a distinct function of catalyzing metabolic reactions. Moreover, the nuclear MTHFD2 activates CDK2 and promotes bladder cancer cell growth by modulating the cell cycle.
Journal
|
CDK2 (Cyclin-dependent kinase 2) • E2F1 (E2F transcription factor 1)
3d
Taken together, the present study investigated the molecular mechanisms underlying the promotion of bladder cancer by KIF22 and provide a novel therapeutic target for the treatment of bladder cancer. Introduction.
Journal
|
CDCA3 (Cell Division Cycle Associated 3) • YBX1 (Y-Box Binding Protein 1)
4d
P1/2, N=56, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Jun 2023 | Initiation date: Feb 2021 --> Jun 2021
Clinical • Enrollment open • Trial completion date • Trial initiation date
|
PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-1 expression
|
AiRuiKa (camrelizumab)
4d
P1b, N=50, Recruiting, NeoTX Therapeutics Ltd. | Trial completion date: Feb 2022 --> Jul 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
|
HER-2 negative • TPBG positive
|
Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
5d
Our results suggest that FAM83H and Nectin1 are important in the progression of BUC, and that expression patterns of these two proteins can be used as prognostic indicators of survival in BUC patients.
Clinical • Journal
|
NECTIN1 (Nectin Cell Adhesion Molecule 1)
6d
There has been a considerable increase in the variety of effective therapies for mUC, including the utility of ICIs, novel targeted agents, and ADCs. Platinum-based chemotherapy remains an effective first-line option. As the role of novel therapies continues to shift toward earlier in the disease course, there remains an important need to develop feasible, globally accessible predictive biomarkers that can aid in patient selection and inform sequencing of therapeutic options.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Bavencio (avelumab)
6d
In vivo, bladder cancer growth in mice was blocked by miR-490-3p upregulation. MiR-490-3p suppressed bladder cancer growth and bladder cancer cell proliferation by down-regulating PCBP2 expression.
Journal
|
MIR490 (MicroRNA 490)
|
miR-490 expression
6d
HMMR knockdown significantly weakened FOXM1 overexpression induced bladder cancer growth, invasion, partial epithelial-to-mesenchymal transition (pEMT), as well as the activation of the Wnt/β-catenin signaling pathway. In conclusion, the findings in this study expanded our understanding of the mechanisms underlying HMMR dysregulation and the functional role of the FOXM1-HMMR axis in bladder cancer.
Journal
|
FOXM1 (Forkhead Box M1)
|
FOXM1 overexpression
7d
In EV-301, a phase 3 trial of patients (pts) with previously treated la/m UC, EV significantly prolonged overall survival (OS) vs chemotherapy (docetaxel, paclitaxel, vinflunine). As of Jun 29, 2021, 150 pts are enrolled (HR+/HER2- BC, n=20; TNBC, n=11). Recruitment is ongoing at ~50 sites in North America and Japan.
P2 data • PD(L)-1 Biomarker • IO biomarker
|
NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HR positive • HER-2 negative • NECTIN4 expression
|
paclitaxel • docetaxel • Padcev (enfortumab vedotin) • Javlor (vinflunine)
7d
These molecular analyses can be carried out on formalin-fixed paraffin-embedded tumor samples and the results should be discussed in interdisciplinary molecular tumor boards in order to either recommend approved targeted therapies or suggest patients for molecular-based clinical trials, compassionate use programs or off-label use of drugs. The remuneration of molecular diagnostics is largely well-represented for the outpatient sector in Germany; however, the covering of treatment costs must currently be approved by the health insurances.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
7d
A decrease in the fraction of circulating PD1+ CD4+ T-cells, and juxtaposition of Th1, CD8+, and myeloid cells was associated with response to anti-PD1 treatment in mUC patients.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ITGAM (Integrin, alpha M)
|
Keytruda (pembrolizumab)
7d
Mechanistically, lnc00892 reduces nucleolin gene transcription by competitively binding the promoter of nucleolin with c-Jun, thereby inhibiting nucleolin-mediated stabilization of RhoA/RhoC mRNA. Taken together, these findings provide novel insights into understanding the mechanisms of bladder cancer metastasis and suggest that lnc00892 can serve as a potential therapeutic target in patients with invasive bladder cancer.
Journal
|
RHOA (Ras homolog family member A) • NCL (Nucleolin) • JUN (Jun proto-oncogene)
7d
Moreover, TR4 mice showed a lower grade of histopathology than the control group. In conclusion, these results indicate that TR4 plays a key role in bladder cancer proliferation, and targeting TR4 would probably be a potential strategy for bladder cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NR2C2 (Nuclear Receptor Subfamily 2 Group C Member 2)
|
BCL2 expression
7d
The classification of blood vessels in BTCC could act as an important prognostic indicator and may also be of great significance in the treatment of cancer.
Journal
|
CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • ENG (Endoglin)
7d
This study provides novel insights into the TME of rare kidney cancer types, which are often understudied. Our findings of differences in marker expression and localization by histological subtype could have implications for tumor progression and response to immunotherapies or other targeted therapies.
Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD68 (CD68 Molecule)
7d
Combination therapy • Trial completion date • Trial primary completion date • Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • ALK translocation
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
|
cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • pemetrexed
8d
P1, N=12, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Sep 2023
Trial completion date • IO biomarker
|
FGFR2 (Fibroblast growth factor receptor 2)
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin)
8d
In this review, we provide a gene expression profile of these channels in different types of cancers and decipher their roles, in particular the roles of two-pore channel 2 (TPC2) and TRPML1 in melanocytes and melanoma. We specifically discuss the signaling cascades regulating MITF and the relationship between endolysosomal cation channels, MAPK, canonical Wnt/GSK3 pathways and MITF.
Review • Journal
|
MITF (Melanocyte Inducing Transcription Factor)
8d
However, sPD-L1 levels were positively correlated with neutrophil to lymphocyte ratios and negatively correlated with both the proportion and the total number of lymphocytes. We found that high pretreatment sPD-L1 levels were associated with progressive disease and were an independent prognostic factor predicting lower PFS and OS in these patients.
Clinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
8d
These results showed multilayer heterogeneity in Ba/Sq MIBC. In view of personalized medicine, this heterogeneity adds complexity and should be taken into account for sampling procedures used for diagnosis and treatment choice.
Journal
|
KRT5 (Keratin 5) • GATA3 (GATA binding protein 3)
8d
DNMT1 rather than DNMT3b knockout in TK6-HT cells activated the expression of UCA1 by inducing its promoter hypomethylation. These results suggest that benzene or HQ exposure leads to UCA1 upregulation via DNA hypomethylation in the UCA1 promoter, which is mediated by DNMT1.
Journal
|
DNMT1 (DNA methyltransferase 1) • DNMT3B (DNA Methyltransferase 3 Beta)
|
hydroquinone
8d
Larger ectosome-like EVs were enriched and separated from apoptotic bodies, smaller exosome-like EVs and soluble particles by sequential centrifugation including high-speed centrifugation. Briefly, cell culture supernatant was centrifuged for 10 min x 300 g; supernatant, 20 min x low speed 2,000 g; supernatant, 40 min x high speed 10,000 g. EVs obtained after high-speed centrifugation were significantly bigger (143.53 ± 15.39 nm) than those at (low speed, 78.44 ± 10 nm).
Preclinical
|
ALK (Anaplastic lymphoma kinase) • FLT3 (Fms-related tyrosine kinase 3) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • EPCAM (Epithelial cell adhesion molecule) • BSG (Basigin (Ok Blood Group)) • S100A4 (S100 calcium binding protein A4)
|
KIT D816V
8d
HRQoL in MIUC patients treated with NIVO was non inferior to patients treated with PBO. Taken together with earlier clinical evidence, these results demonstrate that NIVO prolonged DFS without compromising HRQoL. (Presented at EAU 2021, reused with permission)
Clinical • P3 data • HEOR • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab)
9d
Bladder cancer (BC), one of the most common urological neoplastic disorders in men, has an extremely low survival rate because of its tendency to metastasize. Moreover, additional data revealed that the migrative and invasive effects of BC cells treated with CQ or HCQ were abolished after treatment with rapamycin, which induces autophagy, demonstrating that CQ and HCQ functions in BC are based on autophagy inhibition. In conclusion, our research demonstrated that CQ and HCQ regulated cell motility in BC through MMP-2 downregulation by targeting autophagy functions, providing a novel therapeutic strategy for BC treatment.
Journal
|
MMP2 (Matrix metallopeptidase 2)
|
sirolimus • hydroxychloroquine • chloroquine phosphate
9d
Our study also indicated that DMC showed additive activity in combination with chemotherapeutic agents, including paclitaxel and cisplatin. These findings show that DMC should be developed further as a new antitumor drug candidate for treatment of HER2-overexpressing bladder cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
HER-2 overexpression
|
cisplatin • paclitaxel
9d
P2, N=7, Terminated, Incyte Corporation | Trial completion date: Jan 2026 --> Apr 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Apr 2021; The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.
Clinical • Trial completion date • Trial termination • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
FGFR3 mutation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Pemazyre (pemigatinib)
10d
CA9 mRNA could be detectable in urinary exosomes. The urinary exosomal CA9 mRNA may present a new liquid biopsy for the diagnosis of bladder cancer.
Journal • Liquid biopsy
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
10d
Phosphorylation of several key RTKs targeted by TOC is present in a small subset of primary UC tumors and UC cell lines, suggesting that these RTKs do not exist in a state of continuous activation. These data suggest that activation of RTKs targeted by TOC is present in a small subset of UC tumors and UC cell lines and that treatment with TOC at physiologically relevant concentrations has no direct anti-proliferative effect on UC cells.
Preclinical • Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • KDR (Kinase insert domain receptor)
|
KDR expression
10d
SIRPα TAMs infiltration indicated poor prognosis and ACT resistance in MIBC. Immunosuppressive SIRPα TAMs is closely related to immune evasion with exhausted T cells states, suggesting the prospect of SIRPα TAMs as a potential therapeutic target in MIBC.
Clinical • Clinical data • Journal
|
CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
10d
The signature score is available in the R package "PD1highCD8Tscore" (https://github.com/Liulab/PD1highCD8Tscore). Through estimating the fraction of the PD-1CD8 T cell, our signature could predict response to ICI therapy across multiple cancers and could serve as a complementary biomarker to TMB.
Journal • Checkpoint inhibition • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
10d
The m6A methylation modification was related to the formation of TME heterogeneity and complexity. Assessing the m6A modification pattern of individual bladder cancer will improve the understanding of TME infiltration characteristics.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression
10d
We summarized the chemotherapy regimens and classified them as fluorouracil based, platinum based, and paclitaxel based. Nine patients received XELOX (capecitabine and oxaliplatin) regimens, seven patients received TX (paclitaxel and capecitabine) regimens, and eight of them received chemotherapy including GP (gemcitabine and cisplatin), TP (paclitaxel and cisplatin), TN (paclitaxel and nedaplatin), and tislelizumab...Next-generation gene sequencing revealed TP53 mutation and low tumor mutational burden in five out of seven cases. The platinum-based chemotherapy regimen is effective for relapsed or metastatic urachal carcinoma.
Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)
|
TP53 mutation • TMB-L
|
cisplatin • paclitaxel • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • Baize’an (tislelizumab) • Jie Bai Shu (nedaplatin)
10d
Coprimary end points are event-free survival and pathologic complete response in all patients and in patients with PD-L1 CPS ≥10. Secondary end points are OS, disease-free survival, pathologic downstaging, and safety.
Clinical • P3 data
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • cisplatin • Padcev (enfortumab vedotin)
10d
Aims: In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line maintenance + best supportive care (BSC significantly prolonged overall survival (OS vs BSC alone in patients with advanced urothelial carcinoma (UC without disease progression with first-line chemotherapy (gemcitabine + cisplatin [GemCis] or carboplatin [GemCar]. Observations were similar for progression-free survival.Conclusions : Avelumab first-line maintenance + BSC provided OS benefit vs BSC alone across prespecified subgroups in patients whose disease had not progressed with first-line chemotherapy. These Results support avelumab first-line maintenance as standard of care for patients with advanced UC without disease progression with first-line chemotherapy.
Clinical
|
PD-L1 (Programmed death ligand 1)
|
VENTANA PD-L1 (SP263) Assay
|
cisplatin • carboplatin • gemcitabine • Bavencio (avelumab)
10d
P1, N=52, Active, not recruiting, Adaptimmune | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Pan tumor
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A2 positive
|
afamitresgene autoleucel (ADP-A2M4)
11d
P2, N=81, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
11d
P1, N=152, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • MET expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
11d
P1/2, N=386, Completed, Taiho Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> May 2021
Clinical • Trial completion • Trial completion date
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR fusion • FGFR2 rearrangement
|
futibatinib (TAS 120)
12d
Prunetin possesses anti-cancer properties and may be a candidate compound for the prevention of UBC. This is the first study that evaluated prunetin for its in vitro antitumor activities, clarified its possible apoptotic molecular mechanism and provided novel insights into its anti-inflammatory nature and effects on the expression of related key genes.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
14d
The data presented suggest that IL-2, TRAIL and their MIX proteins in MB49 cells have cytotoxic potential and that this is associated with oxidative stress and apoptosis pathways. These results may contribute to the development of new therapeutic strategies for bladder cancer.
Preclinical • Journal
|
IL2 (Interleukin 2)
14d
AHR (Aryl hydrocarbon receptor)
|
AHR expression
14d
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 expression
14d
We successfully identified three signature genes related to invasiveness and constructed a nomogram of bladder cancer with acceptable performance. Differences suggested by risk scores between groups of patients showing diverse patterns of immune cell infiltration may be beneficial for selecting therapeutic approaches and predicting prognosis.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • PPFIBP2 (PPFIA Binding Protein 2) • CD4 (CD4 Molecule)
14d
The results revealed that sensitivity of all penalties were comparable, but the MCP and MCP-L penalties outperformed the other methods in term of selecting less noninformative variables. The practical use of the model was investigated through the analysis of genomic competing risk data obtained from patients with bladder cancer and six genes of CDC20, NCF2, SMARCAD1, RTN4, ETFDH, and SON were identified using all the methods and were significantly correlated with the subdistribution.
Journal
|
CDC20 (Cell Division Cycle 20)
14d
Moreover, in a tumor model poorly responsive to an initial anti-PD-1 antibody, this vaccine alone significantly inhibited the tumor growth, whereas combination with continuous anti-PD-1 antibody could not inhibit the tumor growth. These results suggest that this oral cancer vaccine alone or as an adjunct to anti-PD-1 antibody could provide a novel treatment option for patients with advanced urothelial cancer including bladder cancer.
Preclinical • Journal
|
WT1 (WT1 Transcription Factor)
14d
SEC61G is overexpressed in HNSCC and is an independent prognostic factor for OS. SEC61G DNA amplification contributes to overexpression and poor outcome. Interestingly, SEC61G correlates with immune cell infiltration in HNSCC. These findings suggest that SEC61G is a potential broad-spectrum biomarker for prognosis in HNSCC.
Journal • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SEC61G (SEC61 Translocon Subunit Gamma)
|
Tecentriq (atezolizumab)
14d
Among these novel interacting proteins are Histone acetyltransferase 1 (HAT1) and all subunits of the heptameric coat protein complex I (COPI) that is involved in vesicle formation and protein cargo binding and sorting. We validate that the HAT1 and COPI interactions occur at endogenous levels but find that this interaction with COPI is not mediated through the C-terminal KxKxx cargo sorting signals of the COPI complex.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BAP1 (BRCA1 Associated Protein 1) • HAT1 (Histone Acetyltransferase 1)
15d
Clinical • New P2 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • PIAS4 (Protein Inhibitor Of Activated STAT 4)
|
PD-L1 expression • PD-L1 underexpression • PD-1 expression
|
cisplatin • Bavencio (avelumab)
15d
PTEN (Phosphatase and tensin homolog) • TSC2 (TSC complex subunit 2)
|
Fyarro (nanoparticle albumin-bound rapamycin)
15d
YAP1 (Yes associated protein 1)
15d
Our data indicate a low incidence rate of MSI tumours in patients with UTUC. Furthermore, our findings highlight that Idylla MSI Assay can be applied as an alternative method of MSI analysis for UTUC.
Journal • Clinical • Microsatellite instability
|
MSI (Microsatellite instability)
|
Idylla™ MSI Test
15d
HYAL-1 and survivin are suitable urine biomarkers for bladder cancer diagnosis.
Retrospective data • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
15d
Journal
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
15d
The addition of endoglin to the preoperative standard model improved its discrimination for prediction of lymph node metastasis, ≥pT3 disease, NOCD, and RFS (differential increases in C-indices: 10%, 5%, 5.8%, and 4%, respectively). Preoperative plasma endoglin is associated with features of biologically and clinically aggressive UCB as well as survival outcomes. Therefore, it seems to hold the potential of identifying UCB patients who may benefit from intensified therapy in addition to RC such as extended lymphadenectomy or/and preoperative systemic therapy.
Journal
|
ENG (Endoglin)
16d
The results indicated that erianin may achieve the above effects via inhibiting the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway in vitro and vivo. Taken together, the results showed that erianin had obvious antitumor effects via inhibiting the PI3K/Akt/mTOR pathway in vitro and vivo and may have potential clinical value for the treatment of lung cancer.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
16d
Examined results undoubtedly showed NNMT as having the capacity to promote cell proliferation, migration and invasiveness, as well as its potential participation in fundamental events highlighting cancer progression, metastasis and resistance to chemo- and radiotherapy. In the light of this evidence, it is reasonable to attribute to NNMT a promising role as a potential biomarker for the diagnosis and prognosis of urologic neoplasms, as well as a molecular target for effective anti-cancer treatment.
Review • Journal
|
NNMT (Nicotinamide N-Methyltransferase)
16d
Urine leukocyte composition may be a useful tool for analyzing the immunological status of MIBC patients. Urine cellular composition allowed us to identify a new subgroup of LN- patients with a higher risk of recurrence.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
16d
In conclusion, whole blood transcriptome profiling identified early changes in DNA replication and cell cycle regulation genes as markers of clinical benefit to anti-PD-1 in patients with urothelial cancer. Although promising, our findings require further validation before implementation in the clinic.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8)
16d
When treated with a combination of nivolumab and ipilimumab drugs, smokers had, on average, reduced HR and FE model meta-analysis values (0.257 and 0.141), respectively. Smokers treated with other drugs have shown worse responses in comparison to non-smokers. These data suggest that, along with the progress in the development of new drugs for cancer, drugs acting on specific genotypes of smokers likely will arise.
Clinical • Review • Journal
|
MUC1 (Mucin 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
16d
p53 expression may be considered as a prognostic factor for the anti-PD-L1 treatment efficacy of low-grade high-PD-L1-positive GATA3(-)/CR5/6(-)-relapsed noninvasive bladder cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • GATA3 (GATA binding protein 3)
|
PD-L1 expression • TP53 mutation • FGFR3 mutation • TP53 expression • FGFR3 expression
16d
We found that Wnt signaling pathway-related genes can be used as prognostic risk factors for BLCA, and the Wnt signaling pathway is a cancer-promoting signaling pathway associated with EMT. We identified three critical genes: MAPK10, RAC3, and PPP2CB. The genes in these three Wnt signaling pathways are associated with tumor cell EMT and immune cell infiltration. The most important finding was that these three genes were independent prognostic factors for BLCA.
Clinical • Clinical data • Journal
|
NCOA3 (Nuclear Receptor Coactivator 3)
16d
Precise subtyping of undifferentiated (urothelial versus RCC and the exact underlying RCC subtype) is best done by thorough sampling supplemented as necessary by immunohistochemistry (e.g. FH, SDHB, ALK) and/ or molecular studies. This review discusses the morphological and molecular genetic spectrum and the recent develoments on the topic of dedifferentiated and undifferentiated genitourinary carcinomas.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • PBRM1 (Polybromo 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • VIM (Vimentin)
|
VIM expression
16d
Increasing evidence supports the theory of bladder cancer development and progression as being partly hormone-dependent. This can lead to a change in conceptual background of bladder cancer etiology and development in the future. Further studies are required to more precise map the use of anti-hormonal drugs in the treatment of this cancer.
Review • Journal
|
ER (Estrogen receptor)
|
tamoxifen
17d
Clinical • New P1 trial • Combination therapy
|
IL2 (Interleukin 2)
|
sasanlimab (PF-06801591) • PF-07263689
17d
Hence, our study suggested that circMBOAT2 may serve as an oncogene in the development and progression of Bca and it will be the novel tumor biomarker and therapeutic target for Bca.
Journal
|
CREB1 (CAMP Responsive Element Binding Protein 1)
17d
Circ_0006948 is upregulated in BC samples, and it is closely linked to tumor stage, metastasis and prognosis in BC patients. It drives proliferative and metastatic abilities in BC cells by activating EMT.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
17d
MiR-363-3p is lowly expressed in BC samples. It weakens in vitro migratory ability in BC cells through downregulating BTG2.
Journal
|
MIR363 (MicroRNA 363)
17d
Treatments with anti-VEGF (Bevacizumab) therapy have been proved to improve relapse-free survival in many tumors...We found that VEGF expression has a significant association with tumor grade and an inverse association with muscle invasion. These findings may be useful for selecting the subset of patients likely to respond to anti-VEGF targeted therapy.
Journal
|
VEGFA (Vascular endothelial growth factor A)
|
VEGFA expression
|
Avastin (bevacizumab)
17d
Based on these results, metformin might be a promising therapeutic agent for canine urogenital tumors. Further studies on kinetics, toxicology, bioavailability, and application of metformin in dogs are necessary.
Preclinical • Journal
|
CD133
|
metformin • dichloroacetate
17d
Clinical • Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1 negative • PD-L1-H
|
cisplatin • carboplatin • gemcitabine • Imfinzi (durvalumab) • tremelimumab (CP-675206)
17d
P1, N=145, Completed, MacroGenics | Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Aug 2021
Clinical • Trial completion • Trial completion date • Combination therapy
|
CD276 (CD276 Molecule)
|
CD276 expression
|
Keytruda (pembrolizumab) • retifanlimab (INCMGA0012) • enoblituzumab (MGA271)
18d
Clinical • Enrollment open • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR T790M negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra SC (tocilizumab SC)
18d
New trial • Liquid biopsy
|
HER-2 (Human epidermal growth factor receptor 2)
|
GuardantREVEAL
19d
P1/2, N=135, Not yet recruiting, Cancer Research UK
Clinical • New P1/2 trial
|
NRG1 (Neuregulin 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
ERBB3 expression • NRG1 fusion • ERBB3 overexpression
|
HMBD-001
19d
These data demonstrate that WNT7B/FZD5-ELF3-NOTCH1 signaling functions as a tumor-suppressing pathway in bladder urothelial carcinoma.
Journal
|
NOTCH1 (Notch 1) • ELF3 (E74 Like ETS Transcription Factor 3)
20d
It showed high values in predicting OS, and targeting these FRGs may be an alternative for BLCA treatment. Further experimental studies are warranted to uncover the mechanisms that these FRGs mediate BLCA progression.
Journal
|
ZEB1 (Zinc Finger E-box Binding Homeobox 1)
20d
This article reviews the abnormal expression of miR-802 in a variety of tumors, expounds the mechanism by which miR-802 affects tumor progression by regulating different target genes, and elaborates the network of miR-802-related ceRNAs. We also summarized the limitations of miR-802 research and looked forward to the potential application of miR-802 in the diagnosis and prognosis of tumors.
Review • Journal
|
IGF2 (Insulin-like growth factor 2)
|
miR-155 expression
20d
Useful diagnostic properties which are commonly attributed to CK5/6 antibodies such as basal cell staining in the prostate, distinction of adenocarcinoma of the lung from squamous cell carcinoma and epithelioid mesothelioma, and identification of basal-type features in urothelial cancer are solely driven by CK5. At least for the purpose of distinguishing thoracic tumors, monospecific CK5 antibodies may be better suited than bispecific CK5/6 antibodies.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • KRT5 (Keratin 5)
20d
The presence of prostatic stromal invasion in non-muscle-invasive bladder cancer upstages the disease, necessitating cisplatin-based neoadjuvant chemotherapy and subsequent cystroprostatectomy...However, these stains do not perform well in cases of UC with squamous differentiation. Thus, D2-40 can be used as an ancillary tool to rule out prostatic stromal invasion.
Journal
|
KRT5 (Keratin 5)
|
cisplatin
21d
Clinical • Retrospective data • Journal
|
CRP (C-reactive protein)
|
cisplatin • gemcitabine
21d
Oridonin exhibited outstanding antiproliferative and antimigratory effects on bladder cancer, and these effects were at least partially associated with targeting of TRPM7 through inactivation of the ERK and AKT signaling pathways. These findings provide insight for the clinical application of oridonin in bladder cancer prevention.
Journal
|
TP53 (Tumor protein P53) • CASP3 (Caspase 3)
|
TP53 expression
21d
Our study constructed a TP53/PIK3CA/ATM mutation classifier to predict the benefit of immune checkpoint inhibitor therapy for patients with bladder cancer. This classifier can potentially complement the tumor mutation burden and guide clinical ICI treatment decisions according to distinct risk levels.
Clinical • Observational data • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • TP53 mutation • PIK3CA mutation • ATM mutation • PD-1 expression
21d
We explored the CXC chemokines superfamily-based biomarkers associated with BLCA prognosis using public databases, and provided possible chemokine targets for patients with BLCA.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • YES1 (YES Proto-Oncogene 1, Src Family Tyrosine Kinase) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • MIR200A (MicroRNA 200a) • HCK (HCK Proto-Oncogene) • RELA (RELA Proto-Oncogene) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
|
CXCL13 expression
21d
In addition, we construct a risk prediction model which could stratify patients with bladder cancer and predict patient prognosis and ICB treatment responsiveness. In conclusion, this study identified effective biomarkers for the prediction of immune checkpoint inhibitor treatment responsiveness in bladder cancer patients and provided new immunotherapeutic targets.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
21d
Furthermore, we found that bladder tumors with HRAS or NRAS activating mutations were dependent on RAF1-mediated signaling and were sensitive to RAF1-targeted therapy. Together, these data identified RAF1 activation as a novel dependency in a subset comprising nearly 20% of urothelial tumors and suggested that targeting RAF1-mediated signaling represents a rationale therapeutic strategy.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
NRAS mutation • HRAS mutation • RAF1 amplification
22d
The GSEA results indicated an immune activation state in DSSH group, which correlated with a down-regulation in the transforming growth factor β receptor signaling pathway. Our study suggests that the activation level of the DDR pathway may be a novel predictive marker for immunotherapy efficacy in patients with mUC.
Clinical • Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • TGFB1 (Transforming Growth Factor Beta 1)
22d
A potential mechanism underlying SPHK1‑induced cisplatin resistance and apoptosis inhibition may be activation of STAT3 via binding non‑POU domain containing octamer binding. In conclusion, the present study suggested that SPHK1 displayed significant antiapoptotic effects in cisplatin‑based treatment, thus may serve as a potential novel therapeutic target for the treatment for bladder cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3)
|
cisplatin • fingolimod
22d
Our study suggests that environmental risk factors in association to NQO1 genotypes (NQO1 609 CT/IVS1-27 CG) play an important role in the development of bladder cancer in Tunisian population.
Clinical • Journal
|
NQO1 (NAD(P)H dehydrogenase, quinone 1)
22d
In our study, CC genotype of IL-18 (-607 C/A) gene variation was determined as genetic risk factor for bladder cancer development. In bladder cancer patient and healthy control groups, G and C allele frequencies of IL-18 (-137 G/C) gene variation, and C and A allele frequencies of IL-18 (-607 C/A) gene variation were determined significantly different from the Hardy-Weinberg distribution.
Clinical • Journal
|
IL18 (Interleukin 18)
23d
Furthermore, Ingenuity Pathway Analysis showed that actin cytoskeleton signaling, tumor microenvironment pathway and mitochondrial dysfunction were significantly enriched by EFEMP1 dysregulation. In conclusion, high EFEMP1 expression was associated with adverse pathological features in UC and independently predicted worse outcomes, suggesting its roles in clinical decision-making and risk stratification.
Journal
|
EGF (Epidermal growth factor)
23d
Based on the results, we concluded that UCA1 promoted LUAD progression and cisplatin resistance and hence could be a potential diagnostic marker and therapeutic target in patients with LUAD.
Journal
|
ENO1 (Enolase 1) • PCNA (Proliferating cell nuclear antigen)
|
cisplatin
23d
In vivo, tumor growth of CRT-resistant T24R cells was abrogated by ATM inhibition using AZD0156. A dataset analysis identified FOXM1 as a putative BUB1B/BUBR1-targeting transcription factor causing its increased expression. These data collectively suggest a redundant role of BUB1B/BUBR1 underlying mutagenic NHEJ in an ATM-dependent manner, aside from the canonical activity of BUB1B/BUBR1 on the G2/M checkpoint, and offer novel clues to overcome CRT resistance.
Journal
|
FOXM1 (Forkhead Box M1) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)
|
AZD0156
23d
GATA3 can also be used as a useful prognostic tool. Although GATA3 is a multi-specific immunohistochemical stain, it is a valuable marker in the panel for confirming many epithelial or mesenchymal neoplasms as both a diagnostic and prognostic tool.
Review • Journal
|
GATA3 (GATA binding protein 3)
23d
P1, N=234, Recruiting, Xencor, Inc. | Trial completion date: Mar 2025 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Jul 2023
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
24d
P2, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Apr 2022 --> Jul 2022
Trial completion date
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression
|
retifanlimab (INCMGA0012)
24d
Clinical • New trial
|
FGFR (Fibroblast Growth Factor Receptor)
|
Balversa (erdafitinib)
24d
Antibodies against human MSH2, MSH6, and MLH1 were cross-reactive with the corresponding canine protein as confirmed using MMR gene knockout canine cell lines. Further studies are required to investigate the clinical outcomes in canine spontaneous tumors with dMMR to determine the potential for immune checkpoint blockade therapy for these tumor types.
Journal • Mismatch repair
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
MSI-H/dMMR
24d
Microsatellite alterations were potentially an independent predictor of CSS in patients with MIBC. The agreement was good between tumor and urine MSI but weak for LOH.
Journal • MSi-H Biomarker
|
MSI (Microsatellite instability) • CTBP2 (C-Terminal Binding Protein 2)
|
MSI-H/dMMR
24d
The median of target gene mRNA expression in grade I/II BC patients was 2.9 for CTLA4 and 6.61 for FOXP3, which was significant compared with the controls (P=0.013 and P=0.0037, respectively). This study highlights the functional activity of Tregs in early stages of bladder cancer and showed the importance of CTLA4 and FOXP3, when it comes to screening BC.
Clinical • Journal • IO biomarker
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
|
FOXP3 expression
24d
It may provide new insight into the function of STC1 in regulating tumor immune microenvironment. Further studies are warranted to uncover the potential mechanisms that mediate STC1 expression and tumor immunity in BLCA.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • STC1 (Stanniocalcin 1)
|
PD-L1 expression
24d
We could not find a significant association between HER2 expression and survival time in BCa patients. Our meta and bioinformatic analysis indicated that HER2 expression was related to pathological malignancy and poor prognosis in BCa.
Retrospective data • Review
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 expression
24d
Therefore, there is a renewed interest in blocking the YAP1/TEAD functions to prevent cancer growth. This review introduces the Hippo pathway components and examines their role and therapeutic potentials in prostate, kidney, and bladder cancer.
Review • Journal
|
YAP1 (Yes associated protein 1)
24d
The research suggests that CNKSR1, POPDC2, and PJA2 may be novel biomarkers as therapeutic targets for MIBC, especially we used immunohistochemical further to validate CNKSR1 as a therapeutic target for MIBC which may help to improve the prognosis for MIBC.
Journal
|
RBBP8 (RB Binding Protein 8, Endonuclease)
24d
It was also found that the expression levels of XBP1, Ki‑67 and EMT‑associated proteins in tumor tissues of the co‑transfection group were markedly restored compared with the circ‑BIRC6 knockdown group. In conclusion, these findings demonstrated that circ‑BIRC6 knockdown suppressed BC tumorigenesis and progression via regulation of the miR‑495‑3p/XBP1 signaling axis, offering a promising therapeutic target for the treatment of BC.
Journal
|
XBP1 (X-box-binding protein 1)
25d
In Russia only one third of patients with mBC received systemic therapy for metastatic disease which affected OS. Consistent with other studies these results indicate that patients should have access to novel therapies.
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
25d
P1b/2, N=261, Completed, Pharmacyclics LLC. | Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Aug 2021 | Trial primary completion date: Nov 2021 --> Aug 2021
Clinical • Trial completion • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
EGFR expression
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • ibrutinib • paclitaxel • everolimus • docetaxel
25d
Clinical • Enrollment closed • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • cisplatin • lenvatinib
27d
In summary, the inhibitory effect of SFN on bladder cancer cell growth and migration is highly dependent on Nrf2-mediated GSH depletion and following production. These findings suggested that a higher dose of SFN is required for the prevention and treatment of bladder cancer.
Journal
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
27d
To our knowledge, this is the first report of Glomangiomyoma of uncertain malignant potential in the urinary bladder which is considered as an unusual variant of atypical glomus tumor. This case emphasizes the importance of broad differential diagnosis which has to be considered in the urinary bladder mass.
Clinical • Journal
|
SYP (Synaptophysin)
27d
Our study and analytical approaches herein provide a rich resource for the further study of cancer stem cells and EMT in the BC research field.
Clinical • Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • NCAM1 (Neural cell adhesion molecule 1)
27d
Therefore, our studies delineated the oncogenic role of CDC20 and its prognostic significance at the pan-cancer level and proved its functional activity in Cdc20 high expression cancer types. Our studies will merits further molecular assays to understand the potential role of Cdc20 in tumorigenesis and provide the rationale for developing novel therapeutic strategies.
Journal • Pan tumor
|
PLK1 (Polo Like Kinase 1) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
CDC20 overexpression
27d
Its expression also increases with stage and poor prognostic factors suggesting its possible role in pathogenesis and progression of urothelial carcinoma. CD 10 may be further analyzed for molecular targeted therapy against urothelial carcinoma.
Clinical • Journal
|
MME (Membrane metallo-endopeptidase)
27d
Finally, the analysis of immunotherapy revealed that the efficacy of CTLA4 or PD1 blockers alone was better in the low-risk group than in the high-risk group. Taken together, we developed and validated a prognostic risk model based on 15 hub genes, which performed well in predicting prognosis and immunotherapy response of BCa patients.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
27d
In addition, high PARP1 expression was positively associated with microsatellite instability event in COAD, KIRP, BRCA, glioblastoma multiforme (GBM), lung squamous cell carcinoma (LUSC), LGG, READ, UCEC, SKCM and LUAD (P < 0.05). Our results highlight the significance of PARP1 alterations as pan-cancer predictive biomarkers for ICI treatment, and its expression levels seem to be correlated with the status of immunotherapy-associated signatures, thus may be a promising biomarker for predicting ICI response in several tumors.
Journal • Tumor Mutational Burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • TMB-H • LAG3 expression • CTLA4 expression • PARP1 overexpression
27d
The candidate biomarker molecules can distinguish between pre- and postoperative urine samples, and alterations in their expression levels are significantly associated with recurrence rates in patients with BC. Therefore, these molecules may become useful biomarkers for the monitoring and prognosis of BC.
Journal
|
CDH2 (Cadherin 2)
27d
The prognostic model based on 4 IArlncRNAs showed an excellent predictive effect. Furthermore, we reasonably speculated that IArlncRNAs are directly or indirectly involved in the immune regulation of the tumor microenvironment (TME), as well as autophagy.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
27d
In the end, our study also shows that the ICI score represents an effective prognostic predictor for evaluating the response to immunotherapy. In conclusion, our study deepened the understanding of the TME, and it provides new ideas for improving patients' response to immunotherapy and promoting individualized tumor immunotherapy in the future.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden)
28d
Urothelial neoplasms are heterogeneous with divergent epithelial and mesenchymal differentiation. Careful morphologic and immunohistochemical evaluation is required to rule out metastatic uterine malignancy, particularly in patients with radiologically evident uterine mass.
PAX8 (Paired box 8)
27d
The association of sarcomatoid features in SCCB is extremely rare, with few cases recorded in literature. The sarcomatoid components described in literature are nonspecific malignant spindle cells, chondrosarcoma, myxoid sarcomatous, osteosarcoma, and rhabdomyosarcoma (Figure 1.95).
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • NKX2-1 (NK2 Homeobox 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • GATA3 (GATA binding protein 3) • SYP (Synaptophysin)
28d
Yolk sac tumor should be considered in the differential diagnosis of a high-grade urothelial carcinoma, particularly when glandular or other unusual architectural patterns are present. A somatic origin with underlying genomic instability similar to what has been described in uterus and ovaries is suggested (PMID: 32558949).
GPC3 (Glypican 3) • NKX2-1 (NK2 Homeobox 1) • POU5F1 (POU Class 5 Homeobox 1) • CDX-2 • SALL4 (Spalt Like Transcription Factor 4) • PAX2 (Paired Box 2) • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • NKX3-1 (NK3 homeobox 1)
28d
Pathologists should be aware of this rare entity as this lesion may be indistinguishable from carcinoma, further emphasizing the importance of tissue diagnosis before definitive surgery. Long-term follow-up in the absence of symptoms may not be required.
APOE (Apolipoprotein E)
28d
Histologic findings in the radical prostatectomy were similar to the features as described above. This rare tumor can be a diagnostic dilemma with adenocarcinomas in adjacent organs; therefore, clinical information, imaging, histology, and immunohistochemical correlation is essential to render a correct diagnosis.
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDX-2 • GATA3 (GATA binding protein 3) • NKX3-1 (NK3 homeobox 1)
28d
We hypothesize that CA19-9 levels may be elevated in some patients postvasectomy, which may explain the positive staining within the vasitis nodosa. CA19-9 staining of vasitis nodosa is a potential pitfall in rare cases of pancreatobiliary and gastrointestinal metastases to the male genitourinary tract.
CDX-2 • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • Cancer antigen 19-9
28d
Our case demonstrated a challenge in diagnosis and ominous clinical outcome because of its resistance to urothelial carcinoma chemotherapy. Further molecular studies are warranted to understand the pathogenesis of the entity and identify druggable targets for management.
Clinical • Clinical data
|
GATA3 (GATA binding protein 3)
28d
Most cases studied showed identical 50-gene molecular profiles in both MPUC and non-MPUC components within the same tumor. This suggests a common clonal histogenesis for both components in these tumors. Therefore, sequencing MPUC components can aid in the detection of mutations for targeted therapies, which may be particularly beneficial given the worse prognosis of this urothelial carcinoma variant.
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
27d
The differential diagnosis for this entity includes mucinous tubular and spindle cell carcinoma, metanephric adenoma, clear cell RCC, and urothelial carcinoma. Awareness of these emerging entities, which may be included in the next WHO classification, is essential to prevent misdiagnosis.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CCND1 (Cyclin D1) • TFE3 • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2) • CTSK (Cathepsin K)
|
CCND1 expression • PAX8 positive
27d
The patient was found to have bilateral lung metastases and was started on pazopanib and close follow-up for possible brain metastasis. ASPS is a rare soft tissue tumor that primarily involves the extremities, and to the best of our knowledge this is only the third case report of primary prostatic ASPS.
Clinical
|
TFE3 • CD31 (Platelet and endothelial cell adhesion molecule 1) • SYP (Synaptophysin)
|
Votrient (pazopanib)
28d
β-catenin has been looked at as a potential differentiator between colonic and bladder adenocarcinoma, showing cytoplasmic staining in primary bladder tumors versus nuclear staining in primary colonic adenocarcinomas. This aligns with our findings.
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDX-2 • GATA3 (GATA binding protein 3)
28d
P2, N=90, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Aug 2021 --> Aug 2022
Clinical • Trial primary completion date
|
ERCC2 (Excision repair cross-complementation group 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
cisplatin • gemcitabine • berzosertib (M6620)
29d
Our study confirmed the contribution of bladder cancer derived exosomes on the establishment of immunosuppressive TME and provided a potential therapeutic target for bladder cancer treatment. Video Abstract.
Journal
|
PTEN (Phosphatase and tensin homolog)
29d
Expression of GATA3 and CK5 did not differ between progressors vs. non-progressors, and were not prognostic for these outcomes. FAP might serve as an easily applicable prognostic biomarker to risk-stratify patients with HG T1 NMIBC if these results are prospectively validated in a larger series.
Journal
|
FAP (Fibroblast activation protein, alpha) • GATA3 (GATA binding protein 3)
|
FAP expression
29d
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
|
Aidixi (disitamab vedotin)
29d
P2, N=19, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2020 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Jun 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Aidixi (disitamab vedotin)
30d
Clinical • New P1 trial
|
CA9 (Carbonic anhydrase 9)
|
Rencarex (girentuximab)
30d
LDH-A and other potential therapeutic targets (MCT4 and GLUT1) were expressed in patient clinical specimens, however, positive staining varied in different areas of sections and with distance from a blood vessel. This intratumoral heterogeneity has important therapeutic implications and indicates the possibility of tumor cell metabolic coupling.
Journal
|
LDHA (Lactate dehydrogenase A) • LDHB (L-lactate dehydrogenase B chain)
30d
MK-1775, a WEE1 inhibitor also known as AZD-1775, blocked proliferation of UC cell lines in a dose-dependent manner irrespective of TP53 status. In conclusion, WEE1 is a promising therapeutic target in the treatment of UC, and a highly specific small molecule inhibitor is currently in early phase clinical trials for cancer. Differential anti-tumor efficacy of WEE1 blockade alone or combined with CDDP may exist according to p53/cell cycle pathway activity, which may be predictable using an ex vivo 3D primary culture system.
Journal • Combination therapy
|
MDM2 (E3 ubiquitin protein ligase)
|
TP53 mutation • TP53 expression • MDM2 overexpression
|
cisplatin • adavosertib (AZD1775)
1m
mTORC1 inhibition with rapamycin analog Ridaforolimus suppresses TRIM28 phosphorylation, hTERT expression, and cell viability. This study may lead to hTERT-directed cancer therapies with reduced effects on normal progenitor cells.
Journal
|
TERT (Telomerase Reverse Transcriptase) • TRIM24 (Tripartite Motif Containing 24)
|
TERT mutation
|
Taltorvic (ridaforolimus)
30d
Response of BC cells to cisplatin, doxorubicin and gemcitabine chemotherapy is modulated by lncRNAs. Noteworthy, anti-tumor compounds and genetic tools such as siRNA, shRNA and CRISPR/Cas systems can regulate lncRNA expression in BC. Finally, lncRNAs and exosomal lncRNAs can be considered as potential diagnostic and prognostic tools in BC.
Preclinical • Review • Journal • IO biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
cisplatin • gemcitabine • doxorubicin hydrochloride
1m
Taken together, this study demonstrated that UBE2S is a carcinogen in UBC and promotes UBC progression by ubiquitously degrading TSC1. This consequently mediates the activation of the mTOR pathway, suggesting a potential therapeutic regimen for UBC by targeting the newly identified UBE2S/TSC1/mTOR axis.
Journal
|
TSC1 (TSC complex subunit 1)
1m
These effects reflected caspase 3-mediated apoptosis and could be attenuated or abolished by inhibiting ROS production with N-acetyl-L-cysteine, inhibiting autophagy with chloroquine, or silencing ATG7 with targeted siRNA...Accordingly, exposure to dorsomorphin (Compound C), an AMPK inhibitor, and AICAR, an AMPK activator, respectively inhibited and stimulated BA-induced autophagy in EJ and T24 cells. The effects of Bmi-1 overexpression in vitro and decreased Bmi-1 expression in BA-treated T24 cell xenografts in nude mice suggested that downregulation of Bmi-1 is the underlying mechanism in BA-mediated, autophagy-dependent apoptosis.
Journal
|
CASP3 (Caspase 3) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • ATG7 (Autophagy Related 7)
|
BMI1 expression
|
chloroquine phosphate
1m
Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment.
Journal • Clinical
|
CA9 (Carbonic anhydrase 9) • SDC1 (Syndecan 1) • MMP9 (Matrix metallopeptidase 9) • APOE (Apolipoprotein E)
|
Oncuria™
1m
Finally, we suspected that the combination treatment of ICI and histone deacetylase inhibitors may achieve better clinical responses in UC patients based on the analysis of drug sensitivity data. In conclusion, our study revealed the predictive value of GMS for ICI efficacy of UC patients, providing a novel perspective for the exploration of new drug targets and potential treatment strategies.
Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
1m
Despite the abundance of correlative studies, the relationship between CRP levels and genitourinary cancer pathogenesis is not clearly understood. Here, we review the evidence for CRP as a biomarker in genitourinary (GU) cancers, with specific focus on potential clinical applications.
Review • Journal
|
CRP (C-reactive protein)
1m
This signature might play an important role in precision individualized immunotherapy. The present work highlights the crucial clinical implications of RNA modifications and may help developing individualized therapeutic strategies for patients with BLCA.
Clinical • Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
1m
It plays a vital role in the proliferation, apoptosis, migration, invasion and epithelial-mesenchymal transformation of various tumor cells. This review summarizes the current body of knowledge on the biological functions and related molecular mechanisms of lncRNA HIF1A-AS2 in the development/progression of human tumors and other diseases.
Review • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression
1m
CN signatures retained great concordance between primary tumor and urinary cfDNA. In conclusion, our results reveal that CN signature assessment for risk stratification is feasible and provides a basis for clinical studies that evaluate therapeutic interventions and prognosis.
Clinical • Clinical data • Journal
|
MSI (Microsatellite instability)
1m
Gene network analyses revealed that exoDNA is associated with cancer, inflammation, and immunity in BC exosomes. Our findings show utility of exoDNA as an objective, non-invasive strategy to identify novel biomarkers and targets for BC.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase)
1m
Furthermore, miR‑218 overexpression blocked the promoting effects of Rab6c on the malignant behavior of bladder cancer cells. Thus, Rab6c promotes the proliferation and invasion of bladder cancer cells, while miR‑218 has the opposite effect, which may provide a novel insight for the treatment of bladder cancer.
Journal
|
MIR218 (MicroRNA 218)
|
miR‐218 overexpression
1m
This study is the first to compare the SP142 antibody in bladder cancer on two different stainers. Our results indicate that both Benchmark Ultra and Bond-III stainers yield highly concordant results using the SP142 PD-L1 antibody.
Journal
|
PD-L1 (Programmed death ligand 1)
|
VENTANA PD-L1 (SP142) Assay
|
Tecentriq (atezolizumab)
1m
In this study, a polymeric nano-sized drug delivery system poly (OEGMA)-PTX@Ce6 (NPs@Ce6) composed of a photosensitizer chlorin e6 (Ce6) and a cathepsin B-sensitive polymer-paclitaxel (PTX) prodrug was constructed...Western blots analysis confirmed that proteins promoting apoptosis (Bax, Cleaved caspase-3, Cleaved PARP) and DNA damage (γH2A.X) were up-regulated, while those inhibiting apoptosis (Bcl-2) and mitosis (pan-actin and α/β-tubulin) were down-regulated after chemo-PDT treatment. Therefore, this stimuli-responsive polymer-PTX prodrug-based nanomedicine with combinational chemotherapy and PDT evaluated in the PDX models could be a potential candidate for bladder cancer therapy.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1)
|
paclitaxel
1m
m-IHC offers significant advantages in characterizing the host immune microenvironment particularly in limited biopsy tissue material. Utilizing a digital image workflow resulted in significant concordance between m-IHC and individual single stains (p < 0.001 for all assessments). Moderate to good agreements were achieved between manual and digital scoring. Our technical work demonstrated potential uses of multiplex marker in assessing the host immune status and could be used in conjunction with PD-L1 as a predictor of response to ICI therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
1m
In COVID-19 patients with cancer, the clinical features and laboratory results between severe group and non-severe group were significantly different. NLR and CRP were the risk factors that could predict death outcome.
Retrospective data • Journal
|
CRP (C-reactive protein)
1m
Immune checkpoint inhibitors (ICIs) are the preferred second-line treatment options for cisplatin-eligible a/m UBC patients and as first-line options in cisplatin-ineligible settings...The recent U.S. Food and Drug Administration approval of erdafitinib and the emergence of other potent and selective FGFR inhibitors (FGFRis) have shifted the treatment paradigm for patients with a/m UBC harboring actionable FGFR2 or FGFR3 genomic alterations, who often have a minimal-to-modest response to ICIs. FGFRi-ICI combinations are therefore worth exploring, and their preliminary response rates and safety profiles are promising. In the present review, we summarize the impact of altered FGFR signaling on a/m UBC tumor evolution, the clinical development of FGFRis, the rationale for FGFRi-ICI combinations, current trials, and prospective research directions.
Review • Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
cisplatin • Balversa (erdafitinib)
1m
A greater understanding of the molecular alterations and immune microenvironment leads to the development of new treatment combinations and targeted therapy. This review summarizes the available evidence concerning the use of immune checkpoint inhibitors and the biological rationale underlying their use in high-grade UTUC.
Clinical • Review • Journal • Checkpoint inhibition • IO biomarker
|
MSI (Microsatellite instability) • FGFR3 (Fibroblast growth factor receptor 3)
1m
The newest indications for monoclonal antibodies are as treatment for homozygous familial hypercholesterolemia, advanced triple-negative breast cancer, advanced urothelial cancer, relapsed or refractory large B-cell lymphoma, and non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion
1m
There is overlap between pulmonary metastatic tumor and primary tumor in morphology. Therefore, the diagnosis should be made by combining clinical history, pathological morphology and immunophenotypic characteristics.
Clinical • Journal
|
NKX2-1 (NK2 Homeobox 1) • CDX-2 • VIM (Vimentin) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • MME (Membrane metallo-endopeptidase)
1m
These findings suggest that XDH is a valuable prognostic biomarker in HCC and other cancers and indicate that it may function in tumor immunology. Loss of XDH expression may be an immune evasion mechanism for HCC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
1m
Our study introduced an important reference for further research on the role of GIlncRNAs, and provided prognostic indicators and potential biological therapy targets for MIBC.
Clinical • Clinical data • Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
1m
This study could not find clinical tools to distinguish responders from non-responders. Further studies preferably with larger cohorts addressing this issue are warranted to improve the selection of patients for neo-adjuvant chemotherapy.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
1m
Mechanistically, we found that the splicing factor, proline- and glutamine-rich (SFPQ) could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression. This study provided a new insight into the relationship between the FTO expression and the m6A RNA methylation, assisting scholars to better understand the pathogenesis of BCa.
Clinical • Journal
|
NOTCH1 (Notch 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • ITGA6 (Integrin, alpha 6)
|
FTO expression
1m
CHEK2 mutations were not associated with any change in bladder or kidney cancer survival regardless of their age, sex, smoking status and family history. We observed a potentially protective effect of CHEK2 mutations on survival for patients with stage T1 bladder cancer. CHEK2 missense mutations were more common among patients with low grade invasive bladder cancer and in patients with stage Ta diease. The frequencies of the I157T CHEK2 pathogenic variant were less in patients with high grade invasive bladder cancer and those with stage T1 disease. Among patients with bladder cancer with stage Ta disease, the OR for any mutation in CHEK2 was 2.0 but for those with stage T1 disease, the OR was 0.3. We observed truncating CHEK2 mutations were associated with kidney cancer patients with GII clear cell carcinoma.
Clinical • Journal
|
CHEK2 (Checkpoint kinase 2)
|
CHEK2 mutation
1m
Clinical • Trial completion date
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation • FGFR fusion
|
gemcitabine • Balversa (erdafitinib) • mitomycin
1m
There was a significant negative correlation between the two markers where high EZH2 and low ARID1A expression was significantly associated with higher tumor grade, stage, presence of muscle invasion, lymph node metastasis, presence of concomitant carcinoma in situ (CIS) and higher incidence of recurrence with shorter RFS rate. It was concluded that EZH2 and ARID1A play a role in tumor carcinogenesis and differentiation and could be considered as independent prognostic factors in UC and for use as a potential therapeutic target.
Journal • IO biomarker
|
ARID1A (AT-rich interaction domain 1A) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
1m
The resultant nanoparticles facilitate the effective low-temperature hyperthermia therapy of muscle-invasive bladder cancer (MIBC) with minimal damage to surrounding heathy tissues. This work delivers a new design concept for development of highly efficient photothermal agents, which also provides a safer approach for noninvasive treatment of MIBC and other malignant tumors.
Journal
|
HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
1m
hILC1s are increased in higher stage tumors among patients with muscle-invasive bladder cancer. These intratumoral hILC1s exhibit an exhausted phenotype and Th17-like differentiation, identifying them as potential targets for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD69 (CD69 Molecule) • IL17A (Interleukin 17A) • IL22 (Interleukin 22)
|
HAVCR2 expression
1m
P1, N=12, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Mar 2021 --> Jan 2022 | Trial primary completion date: Mar 2021 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • IO biomarker
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab)
1m
Clinical • Journal • Checkpoint inhibition • IO biomarker
|
TERT (Telomerase Reverse Transcriptase)
|
TERT promoter mutation • TERT mutation
1m
As a result, the tumor shrunk significantly. Overall, the temporal proteome profiling can systematically reveal the YB1 induced immune responses in tumor, showing great promise for elucidating the mechanism of bacteria-mediated cancer immunotherapy.
Journal
|
CD68 (CD68 Molecule)
1m
ROC curve analysis and a nomogram verified the accuracy of the signature. Through this study, a novel prognostic prediction model for BCa was established based on 9 glycolysis-related lncRNAs that could effectively distinguish high-risk and low-risk BCa patients, and also provide a new point of reference for clinicians to make individualized treatment and review plans for patients with different levels of risk.
Clinical • Journal
|
NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
1m
Positive PD-L1 on TIICs was significantly associated with poorer RFS in "high-risk" patients after RC without AC. Our results support the use of adjuvant immunotherapy in "high-risk" patients with positive PD-L1 on TIICs after RC.
Retrospective data • Journal
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
1m
Our study revealed a ferroptosis-related risk model for predicting prognostic and BC progression. Our results indicate that targeting ferroptosis may be a therapeutic strategy for BC.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1)
|
FGFR3 mutation • RB1 mutation • 6-gene signature
1m
Further multivariate Cox's regression analysis displayed that circ-SMARCA5 high expression was an independent predictive factor for both worse DFS and OS in bladder cancer patients. Circ-SMARCA5 high expression but miR-432 low expression is correlated with advanced tumor features and poor survival of bladder cancer patients, which present as potential prognostic markers in bladder cancer.
Clinical • Journal
|
LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)
1m
Meanwhile, the hypoxia risk score was positively related to the sensitivities of several chemotherapeutic drugs, including Cisplatin, Docetaxel, Paclitaxel, Bleomycin, Camptothecin, and Vinblastine. We developed and validated a new hypoxia risk score, which could predict the clinical outcomes and the TME immune characteristics of BLCA. In general, the hypoxia risk score may aid in the precision medicine for BLCA.
Clinical • Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • LAG3 (Lymphocyte Activating 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
|
cisplatin • paclitaxel • docetaxel • bleomycin • vinblastine
1m
Finally, we analyzed the possible mechanisms of ANXAs in different subtypes of bladder cancer through GO and KEGG analyses and the correlation between ANXAs and immune infiltration in the tumor microenvironment. Taken together, our results indicate that annexins might play important roles in BC and have the potential to be used as markers for subtype classification.
Journal
|
ANXA1 (Annexin A1) • ANXA11 (Annexin A11) • ANXA6 (Annexin A6) • ANXA10 (Annexin A10)
1m
Avelumab is an IgG1 anti-programmed death ligand 1 (anti-PD-L1) monoclonal antibody that has been approved as a monotherapy for metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. Avelumab is cleared faster and has a shorter half-life than other anti-PD-L1 antibodies, such as atezolizumab and durvalumab, but the mechanisms underlying these differences are unknown...These studies suggest that the rapid internalization of avelumab might be due to simultaneous binding of both PD-L1 and FcγR in trans. Our findings also provide a basis to alter the clearance and half-life of monoclonal antibodies in therapeutic development.
Journal
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Inlyta (axitinib)
1m
Lastly, ZMYND8 deficiency was observed to inhibit tumor growth of Bca in vivo, revealing a promising translational significance in Bca treatment. In conclusion, our study for the first time provided evidence for a novel mechanism of FBXW7/ZMYND8 axis in Bca, providing therapeutic vulnerability for individualized cancer treatment.
Journal
|
FBXW7 (F-Box And WD Repeat Domain Containing 7)
1m
P1, N=152, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • MET expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
1m
Inhibition of intestinal cholesterol absorption by Ezetimibe reversed diet-induced hypercholesterolemia and cancer stemness...Lowering serum ox-LDL or targeting the CD36/JAK2/STAT3 axis might serve as a potential therapeutic strategy for UBCs with hypercholesterolemia. Moreover, elevated ox-LDL may serve as a biomarker for UBC.
Journal
|
JAK1 (Janus Kinase 1) • CD36 (thrombospondin receptor)
|
ezetimibe
1m
We additionally analyzed communications between tumor cells and demonstrated its relevance to basal/luminal phenotypes. Overall, our single-cell study provides a deeper insight into the tumor cell heterogeneity associated with bladder cancer progression.
Clinical • Journal
|
SOX2 • SOX9 (SRY-Box Transcription Factor 9)
1m
Clinical • Enrollment open • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
1m
One method is based on delivery of adenoviruses that express Cre recombinase in selected cell types in the urothelium, and a second uses transgenic drivers in which activation of inducible Cre alleles can be limited to the bladder urothelium by intravesicular delivery of tamoxifen...Cross species analyses comparing a mouse gene signature of early bladder cancer with a human signature of bladder cancer progression identified a conserved 28-gene signature of early bladder cancer that is associated with poor prognosis for human bladder cancer and that outperforms comparable gene signatures. These findings demonstrate the relevance of these GEMMs for studying the biology of human bladder cancer and introduce a prognostic gene signature that may help to stratify patients at risk for progression to potentially lethal muscle invasive disease.
Preclinical • Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
|
tamoxifen
1m
Furthermore, the SIRT1-repressed gene signature is associated with the hypoxia target gene signature and poor prognosis in human bladder cancers. Thus, our study demonstrates the power of cancer organoid-based drug discovery and, in principle, identifies SRT1720 as a new treatment for bladder cancer.
Preclinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
1m
The pathological diagnosis was SFT. Since the last surgery, which was performed 30 months ago, no recurrence has been observed.
Clinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule)
|
BCL2 positive
1m
Clinical trial landscape evaluation for emerging therapies was performed by searching ClinicalTrials.gov for recruiting/ open interventional trials in 2020.  Novel treatment modalities for BCG failure include intravesical chemotherapy, BCG re-challenge or combination of BCG with IFN-α2β, valrubicin, radiotherapy, electromotive drug administration, vicinium, chemohyperthermia, photodynamic therapy, gene therapy, vaccine therapy and immunotherapy...However, after 2 or more BCG failures, especially in patients with earlier relapses or cancer persistence, single agent intravesical chemotherapy with valrubicin, gemcitabine or docetaxel appears to be less active than doublet/triplet intravesical chemotherapy or mitomycin chemothermotherapy. Gene therapy or conjugated antibodies may play a role upon further relapse. Single agent pembrolizumab is unlikely to be used as first line, but may be useful, along with multiple new immunotherapeutics, as part of a multimodal approach towards BCG unresponsive disease.  Results from ongoing trials will provide us useful information about many of the existing regimens and probably new drugs will soon be available for this group of patients.
Review • Journal
|
IFNA1 (Interferon Alpha 1)
|
Keytruda (pembrolizumab) • gemcitabine • docetaxel • mitomycin • Vicineum (oportuzumab monatox)
1m
As carbonic anhydrase isoforms in question were not potently inhibited by this compound, its antiproliferative effects likely involve other mechanisms, such as DNA intercalation. Compound 10q clearly represents a viable lead for further development of new-generation anticancer agents.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
1m
Summary receiver operating characteristic curve showed an area under the curve of 0.9544 and Q* index of 0.8965. ApoA-1 showed high sensitivity and specificity, so it could be a useful biomarker in diagnosis of bladder cancer.
Retrospective data • Review • Journal
|
APOA1 (Apolipoprotein A-I)
1m
We also uncovered a paralogous synthetic lethal mechanism behind a genetic interaction between STAG2 and the iron regulatory gene IREB2 Finally, investigation of an unusually strong context-dependent genetic interaction in HAP1 cells revealed factors that could be important for alleviating cohesin loading stress. Together, our results reveal new facets of STAG2 and cohesin function across a variety of genetic contexts.
Journal • Synthetic lethality
|
STAG2 (Stromal Antigen 2)
|
STAG2 mutation
1m
In particular, the safety and clinical benefit of Trop 2-based ADCs have been demonstrated in clinical trials across multiple tumor types, including those with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and heavily pretreated non-small cell lung cancer. In this review, we elaborate on recent advances in Trop 2 targeted modalities and provide an overview of novel insights for future developments in this field.
Review • Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
1m
utDNA MRD detection prior to curative-intent radical cystectomy for bladder cancer correlated significantly with pathologic response, which may help select patients for bladder-sparing treatment. utDNA MRD detection also correlated significantly with PFS. Furthermore, utDNA can be used to noninvasively infer TMB, which could facilitate personalized immunotherapy for bladder cancer in the future.
Journal • Tumor Mutational Burden • IO biomarker • Minimal residual disease
|
TMB (Tumor Mutational Burden)
1m
P1/2, N=82, Recruiting, Klus Pharma Inc. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
1m
Altogether, this study describes a cancer cell population with an intriguing diametric response to major bladder cancer therapeutics. Importantly, it also provides a compelling framework for designing biomarker-guided clinical trials.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CDH2 (Cadherin 2)
|
PD-L1 expression • CDH1 expression
2ms
Similarly, Hoechst staining indicates a remarkable increase in cells with apoptotic morphology after treating with AuNPs. Overall, our findings show that AuNPs significantly provoke ROS production, induce apoptosis, and suppress cell migration in bladder cancer 5637 cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
BCL2 expression • BAX expression • BAX overexpression
2ms
Moreover, PLOD1 downregulation inhibited tumor formation in vivo. This study showed that PLOD1can promote cell growth and aerobic glycolysis through activating the SOX9/PI3K/Akt/mTOR signaling.
Journal
|
LDHA (Lactate dehydrogenase A) • SOX9 (SRY-Box Transcription Factor 9)
|
SOX9 overexpression • SOX9 expression
2ms
In addition to BLCA, IFITM3 is expected to be a marker of high immunogenicity in most human cancers. In conclusion, IFITM3 expression can be used to identify immuno-hot tumors in most cancers, and IFITM3 may be a promising pancancer biomarker to estimate the immunological features of tumors.
Journal • IO biomarker
|
ERBB4 (erb-b2 receptor tyrosine kinase 4)
2ms
The qualitative PCR assay on 10 pairs of bladder cancer and adjacent normal control samples validated the differential expression, and methylated RNA immunoprecipitation (MeRIP) analysis demonstrated a robust m6A enrichment in T24 bladder cancer cells compared with normal uroepithelial cells (SVHUC-1). In conclusion, this study introduced an m6A-related lncRNA signature that identified a subgroup of patients with poor prognoses and suboptimal immune responses, thus providing novel approaches for treatment response prediction and patient stratification in bladder cancer.
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • BDNF (Brain Derived Neurotrophic Factor)
2ms
P1b, N=42, Recruiting, Rahul Aggarwal | Trial primary completion date: Feb 2022 --> May 2023 | Trial completion date: Apr 2022 --> May 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • abexinostat (CG-781)
2ms
The current study shows that tobacco smokers with the NAT2 low acetylator phenotype and GSTM1 null genotype have the highest risk of bladder cancer in the Mongolian population.
Clinical • Journal
|
GSTM1 (Glutathione S-transferase mu 1)
2ms
The differential diagnosis of UCOGC includes other high- grade tumours with giant cells [sarcomatoid urothelial carcinoma, pleomor- phic giant cell carcinoma (PGCC) of the bladder and PGCC of the prostate]. UCOGC usually presents at an advanced stage and its prognosis is very poor.
CD68 (CD68 Molecule) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
2ms
Most common bladder lymphomas are Marginal zone B- cell lymphomas, followed by Diffuse large B-cell lymphomas. This is the second case of concurrence of bladder lymphoma and urothelial carcino- ma reviewed in the literature. In both cases the lymphoid malignant com- ponent was a MZBCL.
Clinical
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II) • GATA3 (GATA binding protein 3) • MME (Membrane metallo-endopeptidase)
2ms
Although rare, sarcomatoid carcinoma is more common than primary bladder sarcoma. Pathologists should be aware of this entity, and to the fact that heterologous elements in the form of rhabdomyosar- coma or other sarcomas may be present in these tumours.
Clinical
|
VIM (Vimentin) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
2ms
Primary angiosarcoma of the urinary bladder is rare. The epithelioid variant of angiosarcoma might be misdiagnosed as high-grade urothelial carcinoma, especially because of positive immunohistochemi- cal staining for cytokeratin.
Clinical
|
CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
2ms
The patient received one cycle of Cisplatin 60 mg/m2 - Adriamycin 60 mg/m2 cycles. Primary urinary bladder sarcomas are uncommon and rep- resents less than 1 % of all urinary bladder malignancies, and osteosar- comas in particular are exceedingly rare. The main differential diagnosis is carcinosarcoma and urothelial carcinomas with osseous metaplasia. However, the distinction from carcinosarcoma does not have major ther- apeutic implications, as both require aggressive therapy, yet the distinc- tion from low-grade urothelial carcinoma with osseous metaplasia is important.
Clinical
|
VIM (Vimentin)
|
cisplatin • doxorubicin hydrochloride
2ms
Marginal Zone B-cell lymphoma of the upper urinary tract is an extremely rare condition and because there are no specific findings on either radiographic or blood examinations pre-treatment diagnosis is diffi- cult. There are around 15 reported cases and in the vast majority of them, the diagnosis was made by nephroureterectomy. Therefore, we consider that the pathological examination is the key to its preoperative diagnosis.
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II) • MME (Membrane metallo-endopeptidase)
|
CD20 positive
2ms
The expression of FAS may play an important role in the prediction of muscle-invasive bladder cancer prognosis. Decrease or loss of FAS expression in tumour tissue indicates aggressive disease and poor survival. Loss of FAS expression in muscle-invasive tumours should impel radical cystectomy with neoadjuvant chemotherapy or trimodal therapy as a mandatory treatment modality.
FAS (Fas cell surface death receptor)
|
FAS overexpression
2ms
Nephrogenic Adenoma is a benign lesion of the urothelial tract which is often misdiagnosed clinically and histologically as a ma- lignancy. Meticulous histological evaluation along with a careful selec- tion of IHC panel is critical for correct diagnosis.
Clinical
|
PAX8 (Paired box 8)
2ms
MSI was statistically significant more often in bladder can- cer (52.0%) than in cervical cancer (4.7%) (p-value = 1.427e-07). A tendency towards a decrease in the expression of the studied MMR pro- teins in the zone of invasive tumour growth was found. An association was found between the absence and/or a decrease in MMR proteins' expression and the degree of differentiation of tumours and stage T. Intratumoral heterogeneity of MMR proteins was noted.
Microsatellite instability • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
2ms
SCC of the bladder occurs more often in elderly males and prognosis is poor; tumour cells are strongly positive for CKAE1/AE3, p53 and focally for CK7, CK20, TTF-1, c-Kit, p63 and are immunoreac- tive for neuroendocrine markers; recognition of this rare entity should enable better detailed tumour clustering when designing clinical trials using drugs targeting patient affected by small cell neuroendocrine phe- notype of urothelial carcinoma.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • NKX2-1 (NK2 Homeobox 1) • NCAM1 (Neural cell adhesion molecule 1) • TP63 (Tumor protein 63) • CHGA (Chromogranin A) • SYP (Synaptophysin)
2ms
Higher expression of both MMP2 and TIMP2 in tumour recurrences suggest a balance between MMPs and their inhibitors activity. Enhancing MMPs inhibitors activity could represent a promising target in a better control and avoiding an unfavourable prognosis.
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
2ms
Positive PD-L1 expression appears to be frequent among UC variants. Our data may provide rationale and further support to in- clude UC variants in clinical trials, in order to identify patients who may benefit of anti-PD-L1 targeted chemotherapy.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
2ms
Postoperatively, the patient received adjuvant chemotherapy (Gemcitabine-Carboplatin protocol) for 6 cycles. Concomitant UC and RCC in the same kidney is extremely rare, with no readily identifiable risk factors for this simultaneous occur- rence, yet 24% of the reported cases were smokers. In our case, RCC was pathologic stage pT1a and the UC was pT3. Pathologists should be aware of the possibility of synchronous renal tumours, as they do rarely occur.
Clinical
|
PAX8 (Paired box 8) • GATA3 (GATA binding protein 3)
|
PAX8 positive
|
carboplatin • gemcitabine
2ms
Anti PD-L1 treatment has been associated with an increase of survival rate. Several studies show different agreement between tests comparing LDT and CDT, reinforcing the importance of ongoing quality control, laboratory personnel training and competency assessment. In our study no relevant technical issues differences were found between PD-L1 clones.
Clinical • Laboratory-developed test • Companion diagnostic • IO Companion diagnostic • PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
2ms
Our study provides evidence for a reduction in BBN-induced bladder cancer by IVI of azacitidine through alterations in the TRAIL-R2 and TNF-R1 signaling pathways. These findings might provide new insights for further clinical trials.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • DNMT1 (DNA methyltransferase 1) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
BIRC5 expression • DNMT1 expression
|
azacitidine
2ms
Again, in low grade bladder tumors, urinary APOA1 protein was exhibited significantly more (52.4% vs. 15.4% high grade) with a higher expression (≥20 ng), while high grade tumor cases (84.6% vs. 47.5% low grade) showed a lower APOA1 expression (<20 ng/mL) (O.R = 6.08, p = 0.002). A strong association was observed between APOA1 -75G/A and risk for bladder tumor and its relation to urinary protein expression, which substantiates its possible role as a marker for the risk assessment of the disease and as a promising diagnostic marker for different grades of malignant bladder tumors.
Journal
|
APOA1 (Apolipoprotein A-I)
2ms
In conclusion, MMP-10 had a higher content, but a lower activity in all investigated tissues compared to MMP-3. Generally, obtained results demonstrated a contrary participation of MMP-3 and MMP-10 in ECM remodeling what may be crucial in the pathogenesis of human urinary bladder carcinoma.
Journal
|
MMP3 (Matrix metallopeptidase 3)
2ms
However, there was no predictive value using a combination of PD-L1 expression and Ki-67 overexpression as a prognostic predictor. Compared with Ki-67 overexpression, a positive PD-L1 expression with CPS ≥ 10 was a stronger independent prognostic factor for CSS in patients with UTUC.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
2ms
In univariable analysis, the prognostic effect of FGFR3 and CDKN2A was observed primarily in patients demonstrating high expression of KRT5 or KRT20, whereas high FGFR3 expression was associated with significantly reduced RFS, irrespective of instillation therapy. Stage T1 NMIBC patients with high FGFR3 expression show shorter RFS but better OS than patients with low FGFR3 expression.
Clinical • Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • KRT5 (Keratin 5) • KRT20 (Keratin 20)
|
CDKN2A negative • FGFR3 expression • CDKN2A expression
2ms
Urinary IL-10 and serum TNF-α can significantly predict ICR. Moreover, change pattern of urinary IL-10, serum CTLA4, TFs (GATA3 , T-bet and FoxP3 ) and GATA3 /T-bet ratio after BCG induction can independently predict further BCG-response. These markers might be implanted in clinical practice when management options are discussed or in systems with severe BCG shortage.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3) • GATA3 (GATA binding protein 3)
2ms
Multivariate Cox regression and stratified analyses further showed that the LAG immunotype was an independent marker of outcome when compared to known clinical prognostic markers and previously described markers for the clinical activity of ICB, PD-L1, and tumor mutation burden. The pretreatment peripheral blood LAG immunotype detects patients who are less likely to benefit from ICB and suggests a strategy for identifying actionable immune targets for further investigation.
Clinical • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
2ms
In conclusion the safety, antitumor activity, and cutaneous pharmacodynamic effects of vemurafenib, and the development of drug resistance in dogs closely mimic those reported in humans. This suggests BRAF-mutated canine InvUC offers an important complementary animal model to improve BRAF-targeted therapies in humans.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF mutation • BRAF V600
|
Zelboraf (vemurafenib)
2ms
By combining the clinical features of BTCC and the expression levels of the three genes, univariate Cox and multivariate Cox regression analyses were performed and denoted that CCNB1 could be used as an independent prognostic factor for BTCC. This study provided potential biomarkers for the prognosis of BTCC as well as a theoretical basis for subsequent prognosis-related research.
Journal
|
CCNB1 (Cyclin B1)
2ms
The deregulation of A-type Lamin is not associated with the prognosis of NMIBC, but it could serve as a diagnostic biomarker distinguishing NMIBC patients from healthy subjects suggesting its involvement as an initiator event of tumorigenesis in our cohort.
Journal
|
LMNA (Lamin A/C)
2ms
Overall, the perturbation of cytoskeleton genes (E-cadherin/N-cadherin) may account for the impact on the motility of T24 cells. Our studies indicate that perfluorinated chemicals might regulate the lncRNAs, thus promoting the metastasis of the tumor cells.
Journal
|
CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MMP2 (Matrix metallopeptidase 2)
2ms
P1, N=45, Recruiting, Mayo Clinic | Trial primary completion date: Jul 2021 --> Jul 2022
Clinical • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • Odomzo (sonidegib)
2ms
Our findings indicated that the genotypes at MMP1 rs1799750 appear to play little role in determining personal susceptibility to bladder cancer for Taiwanese.
Journal
|
MMP1 (Matrix metallopeptidase 1)
2ms
Together, our study demonstrated that plasmacytoid UC belong to the luminal subtype and display a rather inflamed microenvironment similar to conventional UC. These data support the inclusion of plasmacytoid variant of UC in clinical trials evaluating immune checkpoint inhibitors monotherapy or combination immunotherapeutic strategies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
|
PD-L1 expression • HER-2 overexpression
2ms
Tissue PSMA, or FOLH1 expression, may inversely be associated with pathological and survival outcomes in localised UC. PSMA PET imaging may improve detection of metastatic disease and response to systemic therapy due to PSMA expression in neovasculature. Available evidence is limited; thus, larger, prospective studies are required to confirm early results and define populations that benefit most.
Review • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression
2ms
Further experiments revealed that ST8SIA1 could inhibit the phosphorylation of Janus kinase (JAK)2 and STAT3, as well as decrease the expression levels of JAK/STAT pathway-targeting signal molecules, including MMP2, proliferating cell nuclear antigen, cyclin D1 and Bcl2 in two BLCA cell lines. In conclusion, to the best of our knowledge, the present study was the first to indicate that the antitumor effect of ST8SIA1 in BLCA cells was mediated by the JAK/STAT signaling pathway, and the results provided a novel target for the diagnosis and treatment of BLCA.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MMP2 (Matrix metallopeptidase 2) • PCNA (Proliferating cell nuclear antigen)
2ms
Using pathway analysis, those differences imply upregulation of several interconnected inflammatory pathways among responders. Specific variants identified here, namely MCL1, are candidates for further study and, if clinically validated, may serve as useful biomarkers in the future.
Clinical • Journal
|
MSH6 (MutS homolog 6) • ANXA10 (Annexin A10)
2ms
P3, N=739, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab)
2ms
These data suggest that the B8T signature can enhance OS stratification in patients with advanced urothelial carcinoma who are treated with ICI therapy and that sex-specific differences in the tumor immune microenvironment may drive disparate outcomes.
Journal • Checkpoint inhibition • Tumor Mutational Burden • Gene Signature • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
|
TMB-H
|
Tecentriq (atezolizumab)
2ms
Neoadjuvant gemcitabine and cisplatin plus pembrolizumab met its primary end point for improved pathologic downstaging and was generally safe. A global study of perioperative chemotherapy plus pembrolizumab or placebo is ongoing.
Clinical • P2 data • Journal
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • cisplatin • gemcitabine
2ms
Using a zebrafish model, injection of iNOS- or rictor-silenced cells reduced the frequency of bladder cancer cell metastasis in zebrafish. These results indicate that mTORC2 can mediate bladder cancer cell invasion through increased iNOS expression, resulting in increased NO and cGMP production in invadopodia and further propagation of invadopodia formation.
Journal
|
NOS3 (Nitric oxide synthase 3)
2ms
P2b, N=145, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Jun 2021 --> May 2023
Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Anktiva (inbakicept) • PD-L1.t-haNK
2ms
Our research suggests that a new gene model related to ferroptosis can be applied for the prognosis prediction of BLCA. Targeting FRGs may be a treatment option for BLCA.
Clinical • Journal • Gene Signature
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • SLC7A11 (Solute Carrier Family 7 Member 11) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
ZEB1 expression
2ms
Our results indicate that levofloxacin has broad-spectrum anticancer activity with the potential to benefit cancer patients already treated or requiring prophylaxis for an infectious syndrome. The efficacy we find with levofloxacin may provide insight into the discovery and the design of novel less toxic anticancer drugs.
Journal
|
THBS1 (Thrombospondin 1)
|
levofloxacin
2ms
HE based sTIL scoring is a reliable tool to assess MIBC inflammation status and to stratify the survival of MIBC patients undergoing radical cystectomy. sTIL amount is an independent predictor for improved survival, and might be an useful, routinely applicable tool to identify patients benefiting from perioperative platinum-based chemotherapy and checkpoint inhibitor therapy. However, external validation of our data is required.
Clinical • Journal • Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule)
2ms
Repeated cycles of first-line chemotherapy drugs such as doxorubicin (DOX) and cisplatin (CIS) trigger frequent chemoresistance in recurrent urothelial bladder cancer (UBC). These results suggested that NTX-induced P-gp reversal, G0/G1 arrest, and apoptosis in drug-resistant UBC were mediated by inhibition of STAT3 signaling. Our findings repurpose NTX as a novel STAT3 inhibitor to induce P-gp reversal, G0/G1 arrest, and apoptosis in drug-resistant UBC.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • CDK4 (Cyclin-dependent kinase 4) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CDK6 (Cyclin-dependent kinase 6)
|
cisplatin • doxorubicin hydrochloride • nitroxoline
2ms
Our results supported the perspective that depression exacerbated bladder cancer and revealed a possible mechanism. We suggest attaching importance to the psychological health of bladder cancer patients to prevent a worse prognosis induced by depression.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
2ms
Subsequent analyses by using some bioinformatics and experimental assays confirmed that CD86 was an immune-related prognostic biomarker, which might be a novel target for immunotherapy in BC. A small molecule drug named suloctidil was also identified, which showed potential for BC treatment.
Clinical • Journal • IO biomarker
|
CD86 (CD86 Molecule)
2ms
The results of our study indicated that a novel prognostic model based on the nine-FRG signature can be used for prognostic prediction in BC patients. FRGs are potential prognostic biomarkers and therapeutic targets.
Journal • Gene Signature
|
IFNG (Interferon, gamma) • FANCD2 (FA Complementation Group D2)
2ms
We constructed MIBC subtyping models based on multi-omics data and single omics data, respectively, and internal and external validation datasets showed the robustness of the prediction model as well as its ability of prognosis (P < 0.05 in all datasets). Finally, through bioinformatics analysis and immunohistochemistry experiments, we found that KRT7 can be used as a biomarker reflecting MIBC risk.
Journal
|
IL6 (Interleukin 6) • KRT7 (Keratin-7)
2ms
In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
2ms
Moreover, our findings provided potential clinical significance for patients with lymph node-only metastasis or primary tumor in the lower tract. However, these exciting findings need further confirmation.
Retrospective data • Journal • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
2ms
P2, N=154, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2021 --> Sep 2023
Clinical • Trial completion date • Combination therapy
|
HRD (Homologous Recombination Deficiency)
|
Lynparza (olaparib) • Imfinzi (durvalumab)
2ms
P1/2, N=12, Recruiting, Telix International Pty Ltd
Clinical • New P1/2 trial
|
CA9 (Carbonic anhydrase 9)
|
Rencarex (girentuximab)
2ms
P1b, N=40, Recruiting, The Netherlands Cancer Institute | Not yet recruiting --> Recruiting
Enrollment open • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
2ms
P2, N=25, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
|
Aidixi (disitamab vedotin)
2ms
Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the mitogen-activated protein kinase (MAPK) signaling pathway, focal adhesion pathway, and Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling pathway were enriched in a high-risk score pattern, suggesting that imbalance in these pathways is closely related to tumor development. We revealed the prognosis-related lncRNAs by analyzing the expression profiles of lncRNAs and CNVs, which can be used as prognostic biomarkers for BLCA.
Journal
|
NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
2ms
In conclusion, CRPBsites is an effective prediction model for circRNA-RBP interaction site identification. We hope that CRPBsites can provide valuable guidance for experimental studies on the influence of circRNA on post-transcriptional regulation.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
2ms
A novel genomic-clinicopathologic nomogram to improve prognosis prediction of bladder cancer was further plotted and calibrated. Our study deepens the understanding of the regulatory ceRNA network and provides an easy-to-do genomic-clinicopathological nomogram to predict the prognosis in patients with bladder cancer.
Journal
|
NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
2ms
When faced with papillary groups in a voided urine specimen, the cytopathologist must remember to consider a broad differential diagnosis to include malignancies outside of the urinary tract. It was our awareness of valuable clinical information and keen cytologic assessment which allowed for an accurate diagnosis in the setting of this unexpected finding.
Clinical • Journal
|
PAX8 (Paired box 8) • GATA3 (GATA binding protein 3)
|
PAX8 positive
2ms
P1, N=115, Recruiting, Cancer Research UK | N=68 --> 115
Clinical • Enrollment change
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
LY3143921
2ms
P2, N=80, Active, not recruiting, Erasmus Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Aug 2023 | Trial primary completion date: Aug 2019 --> Aug 2022
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
TMB (Tumor Mutational Burden)
|
Keytruda (pembrolizumab)
2ms
The experimental group was administered with temozolomide (5mg/kg/day) by oral gavage, Hsp90 inhibitor Onalespib (30mg/kg/day) by tail vein injection or the combination of the two for indicated days. F3-T3 is a strong Hsp90 client that shows strong addiction to the Hsp90-Cdc37 chaperone system. Combination therapy with Hsp90 inhibitor overcomes the TMZ resistance conferred by F3-T3.
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
FGFR3 fusion • FGFR3 expression
|
temozolomide • onalespib (AT13387)
2ms
Increasing miR-20a is closely related to aggressive clinicopathological features. MiR 20a plays an oncogenic role in bladder cancer, which contributes to target LASS2 directly.
Journal
|
MIR20A (MicroRNA 20a)
2ms
Our analysis effectively provides a newly TFs-associated prognostic model for bladder cancer. The combination of five identified-TFs is an independent prognostic biomarker, which could serve as a more effective therapeutic target for BCa patients.
Journal
|
NFATC1 (Nuclear Factor Of Activated T Cells 1)
2ms
Journal
|
CD44 • VIM (Vimentin) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL5 (Chemokine (C-X-C motif) ligand 5)
|
CD44 expression • VIM expression
2ms
The developed countries in America and Europe are leading the trend of bsAbs research. Anticancer bsAbs clinical research in China is booming and chasing after the world trend.
Journal
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
2ms
In summary, for the first time our study demonstrates the in vivo tumor suppressor activity of RNF144A upon carcinogenic insult. Loss of RNF144A promotes the expression of DNA-PKcs, BMI1 and PD-L1, likely contributing to the carcinogen-induced bladder tumorigenesis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • GATA3 (GATA binding protein 3)
|
EGFR expression
2ms
P2, N=56, Recruiting, European Association of Urology Research Foundation | Trial completion date: Jan 2024 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Apr 2024
Clinical • Trial completion date • Trial primary completion date
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
FoundationOne® CDx
|
Pemazyre (pemigatinib)
2ms
P4, N=50, Recruiting, Germans Trias i Pujol Hospital | Trial completion date: Jul 2021 --> Mar 2022 | Trial primary completion date: Jul 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date
|
FGFR3 (Fibroblast growth factor receptor 3) • CDH1 (Cadherin 1) • CD14 • KRT14 (Keratin 14) • CDH2 (Cadherin 2) • G0S2 (G0/G1 Switch 2) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • KRT5 (Keratin 5) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KRT20 (Keratin 20)
2ms
P2, N=376, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2023 --> Jun 2022 | Trial primary completion date: Jun 2023 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • EGFR mutation • EGFR T790M
|
spartalizumab (PDR001) • taminadenant (NIR178)
2ms
P2, N=202, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2021 --> Mar 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Tecentriq (atezolizumab)
2ms
P1, N=32, Active, not recruiting, University of California, Davis | Trial completion date: Apr 2021 --> Dec 2021
Clinical • Trial completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • gemcitabine • docetaxel
2ms
Radical surgical treatment is recommended and to date there is no proven effective adjuvant treatment. Its median overall survival is 15 months.
Clinical • Journal
|
CD68 (CD68 Molecule)
2ms
The final BLBT, as well as all BBTs, HGSC, OEC, and HGUC, were negative for MDM2. In conclusion, our limited cohort confirms MDM2 amplification in MBT and suggests that MDM2 IHC may have an influence in rare diagnostically challenging cases.
Journal
|
MDM2 (E3 ubiquitin protein ligase)
|
MDM2 amplification
2ms
The anticancer effect of HNK may be due to the activation of the caspase pathway and inhibition of phosphorylation of NF-κB, Akt, and ERK. HNK in combination with HCPT produces a synergistic cell-killing effect on bladder cancer cells.
Journal • Combination therapy
|
CASP3 (Caspase 3) • CASP9 (Caspase 9)
2ms
Histological variants and CAIX immune-expression are biomarkers of nonresponse to NAC of MIBC, and might be easily used in the clinical practice to select patients to be submitted to surgery upfront.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • CA9 (Carbonic anhydrase 9) • KRT5 (Keratin 5) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
|
CA9 expression
2ms
Also, TERT promoter mutation has great potential for diagnosis, as well as prognosis in UC treatment, and this is also applicable for the liquid biopsy techniques. In this review, we discuss the progress in these areas and highlight the challenges, clinical potential, and future direction for developing UC treatment methods.
Clinical • Review • Journal
|
TERT (Telomerase Reverse Transcriptase)
|
TERT promoter mutation • TERT mutation
2ms
These findings suggested that hBSC-derived exosomal miR-217 may act as oncogene in bladder cancer cells, and that Hippo-YAP signaling pathway maybe the target for miR-217 in the bladder cancer cell lines.
Journal
|
ANKRD1 (Ankyrin Repeat Domain 1) • CTGF (Connective tissue growth factor) • MIR217 (MicroRNA 217)
2ms
Our data suggest that in the process of selection of the patients who will benefit the most from targeted therapies, it is particularly important to select the appropriate molecular diagnostic method.
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
2ms
Recurrence was not observed on MRI taken 6 months after the surgery. Paraurethral leiomyoma is rare, but relatively common in young women.
Clinical • Journal
|
PGR (Progesterone receptor)
2ms
All FFPE exome capture-based methods had comparable performance and concordance with FF-TruSeq. Our findings will enable the implementation of RNA-seq in the clinic to guide precision oncology approaches.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
|
HER-2 expression
2ms
The altered expression of CD39 presented herein supports the idea that this ectonucleotidase may be involved in bladder tumorigenesis. High expression of CD39 in tumor cells is correlated with the early stage of BC.
Journal
|
CD73 (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • NT5E (5'-Nucleotidase Ecto)
|
CD73 expression
2ms
Importantly, our noninvasive biosensing approach is capable of quantifying statistical differences using 5 biomarker levels between BC patient urine samples (Stage T1-T4) and healthy samples. Early Is Good will be ready to apply BCDx testing to a larger patient population to further validate BCDx as an effective, noninvasive, and robust follow-up and diagnostic test for the BC community.
Clinical
|
MIR10B (MicroRNA 10b)
2ms
This study suggests the importance of the diversity and specificity of HLA-B loci in the antitumor effect of BCG immunotherapy for NMIBC. These findings may contribute to the delineation of risk strata for BCG therapy and improve the medical management of NMIBC.
Journal
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
2ms
P2, N=30, Active, not recruiting, Matthew Galsky | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • POLE (DNA Polymerase Epsilon) • ERCC2 (Excision repair cross-complementation group 2) • ATRX (ATRX Chromatin Remodeler) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD54L (DNA Repair And Recombination Protein RAD54) • BRCA (Breast cancer early onset) • FANCF (FA complementation group F) • ERCC5 (ERCC Excision Repair 5 Endonuclease 2) • RAD52 (RAD52 Homolog DNA Repair Protein) • WRN (WRN RecQ Like Helicase) • XRCC2 (X-Ray Repair Cross Complementing 2) • FANCD2 (FA Complementation Group D2) • FANCG (FA Complementation Group G) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RECQL4( RecQ Like Helicase 4) • ERCC3 • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • FANCC (FA Complementation Group C)
|
Lynparza (olaparib)
2ms
P2, N=160, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
New P2 trial
|
CRP (C-reactive protein)
|
Resolor (prucalopride)
2ms
The genetic analysis was highly concordant with histopathological features and added prognostic information in some cases. Thus, results from genomic profiling may contribute to the choice of treatment and follow-up regimens in the future.
Journal • Tumor Mutational Burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
TP53 mutation • HRAS mutation • FGFR3 mutation
2ms
Enrollment open
|
TMB (Tumor Mutational Burden)
2ms
The potential of hsa_circ_0007813 in regulating IGF2R expression explained its influence on cell behavior and clinical outcomes. Collectively, our data could offer new insight into the biology of circRNA in bladder cancer.
Journal
|
IGF2R (Insulin Like Growth Factor 2 Receptor) • MIR361 (MicroRNA 361)
2ms
The expression of SLC12A8 was positively correlated with crucial immune checkpoint molecules. In conclusion, SLC12A8 might be an unfavorable prognostic biomarker in BC related to tumor immune cell infiltration.
Journal
|
CD4 (CD4 Molecule)
2ms
We constructed a risk prediction signature with six homeobox genes, which showed good accuracy and consistency in predicting the patient's prognosis and response to immunotherapy. Therefore, this signature can be a potential biomarker and treatment target for BLCA patients.
Journal • IO biomarker
|
MEIS1 (Meis Homeobox 1)
2ms
Enrollment open
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin)
2ms
We further determined that the microbes we profiled were likely not environmental contaminants. In conclusion, we discovered that the intra-tumoral microbiome could potentially play a significant role in the regulation of EMT in MIBC.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CDH1 expression
2ms
Finally, in vitro studies showed siRNA-mediated CNGB1 knockdown enhanced cisplatin sensitivity of MIBC cell lines, J82 and 253JB-V. Overall, these data reveal a novel signature gene set and CNGB1 as a simpler proxy as a promising biomarker to predict chemoresponsiveness of MIBC patients.
Clinical • Journal • IO biomarker
|
IDO1 (Indoleamine 2,3-dioxygenase 1)
|
cisplatin
2ms
These tumor entities need to be considered in cases of PLAP-positive metastasis. Low-level PLAP expression can be found in various other tumor entities and should generally not be viewed as a strong argument for germ cell neoplasia.
Journal
|
ALPP (Alkaline Phosphatase, Placental)
|
ALPP expression
2ms
GSPs also inhibited TGF-β-induced phosphorylation of Smad2/3, Akt, Erk, and p38 in 5637 cells without affecting the expression of total Smad2/3, Akt, Erk, and p38. Taken together, the results of the present study demonstrate that GSPs effectively inhibit the migration and invasion of BC cells by reversing EMT through suppression of the TGF-β signaling pathway, which indicates that GSPs could be developed as a potential chemopreventive and therapeutic agent against bladder cancer.
Journal
|
CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • SNAI2 (Snail Family Transcriptional Repressor 2) • TJP1 (Tight Junction Protein 1)